Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM9KNJT)

Drug Name
Vobarilizumab Drug Info
Synonyms ALX-0061
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Phase 2 [1]
Systemic lupus erythematosus 4A40.0 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DM9KNJT

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 6 receptor (IL6R) TT0E5SK IL6RA_HUMAN; IL6RB_HUMAN Inhibitor [3]
Serum albumin (ALB) TTFNGC9 ALBU_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Serum albumin (ALB) DTT ALB 7.535 2.536 4.755 4.7
Interleukin 6 receptor (IL6R) DTT IL6R 6.42 5.564 5.031 5.404
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Rheumatoid arthritis
ICD Disease Classification FA20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 6 receptor (IL6R) DTT IL6R; IL6ST 5.77E-01 -0.24 -0.47
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02518620) An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02437890) A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Ablynx.